Paroxetine compositions and processes for making the same

ABSTRACT

Paroxetine salt compositions having improved stability are formed by controlling the pH to 6.5 or less. The compositions can be made with the aide of water without significant coloration problems. The paroxetine salts include paroxetine hydrochloride salts but preferably use paroxetine sulfonate salts such as paroxetine methane sulfonate.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority under 35 U.S.C. §119(e) from prior U.S. provisional application serial No. 60/228,110filed Aug. 28, 2000 and from prior U.S. provisional application serialNo. 60/234,936 filed Sep. 26, 2000: the entire contents of each of theaforementioned provisional applications being incorporated herein byreference.

BACKGROUND OF THE INVENTION

[0002] 1. Field of the Invention

[0003] The present invention relates to a paroxetine compositions,especially pharmaceutical formulations and dosage forms, and toprocesses of manufacturing the same.

[0004] 2. Description of the Related Arts

[0005] U.S. Pat. No. 4,007,196 describes certain compounds that possessanti-depressant activity. One specific compound mentioned in this patentis known as paroxetine and is represented by the following formula:

[0006] Paroxetine has been approved for treating, inter alia, depressionin humans and is being marketed around the world under such brand namesas Paxil® (SmithKline Beecham) and Seroxat. Dosage forms thus farinclude immediate release tablets, extended release tablets, capsulesand suspensions. The active substance in all commercial forms thus farhas been paroxetine hydrochloride and specifically with regard totablets and other solid forms the active has been paroxetinehydrochloride hemihydrate as disclosed in U.S. Pat. No. 4,721,723 and EP223403.

[0007] WO 95/16448 reports that all commercial paroxetine hydrochloridehemihydrate tablets were, at least up until that time, made using a wetgranulation process. Further, the commercial tablets exhibited a colorchange; i.e., these tablets often developed a pink hue that is highlyundesirable. This was apparently masked in the commercial product by acolored outer coat layer. The point of the PCT publication is that thepink hue formation can be avoided by carrying out tableting in theabsence of water, i.e. by conventional dry granulation and directcompression. The PCT publication does not mention what the coloringcompound(s) are or their route of formation. But, subsequent documentsreveal that the coloration problem involves the formation of a coloringimpurity identified below as the compound of formula A.

[0008] Since the publication of WO95/16448, it appears that the brandname paroxetine hydrochloride hemihydrate product in Europe, at least,was changed to a dosage form made by a dry granulation technique inaccordance with the teachings in the PCT publication.

[0009] It would be advantageous to find a paroxetine composition thatdoes not suffer from coloration or that is less prone to colorationregardless of how the composition is made. Further, it would bedesirable to make a paroxetine composition with the aid of water, suchas by wet granulation, that nonetheless was not prone to theabove-mentioned coloration problems.

[0010] In particular, the application of an aqueous granulation processfor industrial scale production is desirable in that such a processprovides uniform distribution of the active substance within the bulkgranulate composition so that the dose uniformity of tablets or capsulesis more easily assured. This is especially true in the case of unitdosage forms containing a low dose of a potent active agent. Here,paroxetine is normally used in 20 to 40 mg per tablet and thus itsuniformity in large scale production could be of concern. Water is avery suitable solvent for the granulation process because it isnon-toxic and non-flammable. Thus, it would be desirable to find a wayto use an aqueous granulation process for the industrial scaleproduction of paroxetine final forms that would also avoid or limit theoccurrence of the color forming impurities.

[0011] U.S. Pat. No. 5,874,447 describes paroxetine sulfonate salts,including paroxetine methane sulfonate also known as paroxetinemesylate. These sulfonate salts have advantageous properties incomparison to the known salts, including the hydrochloride salts. Forexample, the sulfonate salts have high water solubility and good thermalstability, making them useful in forming a commercial paroxetine dosageform. The U.S. Pat. No. 5,874,447 patent discloses that tablets can bemade by any known method including a dry technique (direct compression,dry granulation) or a wet technique (wet granulation). However, nodiscussion appears in the 5,874,447 patent regarding the paroxetinehydrochloride coloring problem.

SUMMARY OF THE INVENTION

[0012] Now, it has surprisingly been discovered that solid paroxetinecompositions including granulates and dosage forms made therefrom, canbe made more stable against coloration, even if made with the aid ofwater such as by an aqueous granulation process, by controlling the pHof the composition to 6.5 or less. Further, it appears that paroxetinesulfonate salts are less prone to coloration problems than paroxetinehydrochloride salts, even if made with the assistance of water. Studiesby the present inventors reveal that the impurity A is a dimer formedfrom the paroxetine free base in an aqueous alkaline environment. Oxygenis also apparently needed to allow the dimer reaction to proceed. Giventhe discovery that coloring impurity A is formed in the presence ofwater, it is understandable in hindsight how carrying out a dry processas suggested in WO95/16448 would help to minimize and/or avoidcoloration; i.e. the required aqueous medium for forming the dimericimpurity is missing thereby inhibiting its formation. Having elucidatedthe source of the coloring problem, the present invention provides anovel solution thereto by keeping the pH of the composition to 6.5 orless. Alternatively, the present invention unexpectedly solves thecoloring problem by switching the paroxetine salt from hydrochloride tosulfonate and thereby allowing the use of water in the preparation ofparoxetine granules without incurring any substantial coloration.

[0013] Thus, in a first aspect of the invention, there is provided asolid paroxetine composition comprising a paroxetine salt and anexcipient wherein said composition has a pH of 6.5 or less, as ishereinafter defined. The paroxetine salt is preferably a paroxetinesulfonate salt such as paroxetine methane sulfonate or a paroxetinehydrochloride salt. The excipients generally include a binder or diluentsuch as calcium phosphate or microcrystalline cellulose as well as adisintegrant and lubricant. The composition can be an intermediate formor a final dosage form such as a tablet or capsule. In one embodiment, atablet is made that does not need a taste masking coating to avoid theusual bitter taste associated with paroxetine compositions.

[0014] A second aspect of the present invention relates to paroxetinesolid dosage forms comprising a paroxetine sulfonate salt as apharmaceutically active agent and having been made with the aid ofwater. The solid dosage form can be a tablet, pellet or capsule form,etc., and contains a pharmaceutically effective amount of paroxetinesulfonate, e.g. for treating depression, obsessive-compulsive disorder,or panic attack, etc. Preferably the excipients are selected so that thecomposition has a pH of 6.5 or less. Further, the composition isnormally dried to a sufficient extent that the total content of addedwater remaining is 2.0 wt % or less, preferably 1.3 wt % or less, andmore preferably 1.0 wt % or less. Generally, the composition does notcontain any decolorization agent as an excipient. Even though an aqueousprocess is used, the dosage form of the present invention exhibits no,or substantially no, formation of a pink or other colored hue.

[0015] A third aspect of the invention provides for a granulate formedby mixing water, paroxetine sulfonate salt, and at least one excipientand drying the resulting mixture. Typically the water and paroxetinesulfonate salt are provided together as an aqueous solution and added tothe powdered or dry excipient(s), although this is not required. In someembodiments, the excipient(s) may be pre-blended and granulated such asby a dry granulation technique before being contacted with aconcentrated aqueous paroxetine sulfonate salt solution. The mixture isdried to form a granulate to which additional excipients may be added,if desired. The granulate can be formed into other conventional dosageforms such as tablets, capsules, sachets, pellets, etc. The compositionis preferably selected as described above for the dosage forms, namelywith a pH of 6.5 or less and with an added water content of 2.0 wt % orless.

[0016] A fourth aspect of the invention provides a process for makingpharmaceutical compositions which comprises mixing paroxetine sulfonateand at least one excipient with the aid of water. In one convenientembodiment, an aqueous solution containing at least 10 wt % of aparoxetine sulfonate salt is added to at least one solid excipient anddried to form a granulate. Preferably, the aqueous solution is a highlyconcentrated aqueous solution of paroxetine sulfonate salt having aconcentration of not less than 30 wt %. This process can be usedadvantageously to form the granulates described above which can besubsequently processed into the above-described dosage forms.Alternatively, water can be added to a powder bed of paroxetinesulfonate and one or more excipients and the mixture dried to formgranules.

[0017] A preferred paroxetine sulfonate salt for use in all aspects ofthe present invention is paroxetine methanesulfonate, also calledparoxetine mesylate. Paroxetine mesylate is compatible with many commonpharmaceutical excipients useful in aqueous granulation procedures,which makes the process reliable on an industrial scale.

DETAILED DESCRIPTION OF THE INVENTION

[0018] The present invention relates to solid paroxetine compositionsthat resist the formation of a color hue and to processes for making thesame with the aid of water. As used herein, the expression “made withthe aid of water” means that water is added during some aspect of theformation process of the composition but is substantially or completelyremoved in the final composition. The water can be added to excipients,to the paroxetine salt especially paroxetine sulfonate salts, or toboth. The solid compositions of the invention include solid dosage formssuch as tablets, capsules, sachets, etc., and intermediate forms such asgranules or pellets.

[0019] Paroxetine salts used in the present invention arepharmaceutically acceptable salts, i.e., acid addition salts. Preferredsalts include paroxetine hydrochloride salts and paroxetine sulfonatesalts. The paroxetine hydrochloride salt can be of any form includingthe paroxetine hydrochloride hemihydrate form and paroxetinehydrochloride anhydrate forms. The paroxetine sulfonate salts used inthe present invention can be any salt of paroxetine where the an anioncontains a sulfonate group; i.e. the moiety —S(O₂)OH. Preferredsulfonate salts include those having the following structural formula:

[0020] wherein R represents a C₁-C₁₀ substituted or unsubstituted alkylgroup or a substituted or unsubstituted aromatic group wherein thesubstituents are selected from the group consisting of C₁-C₁₀ alkyl,halogen, nitro, hydroxy, alkoxy, and combinations thereof. Preferredparoxetine sulfonate salts include those having a solubility in water ofat least 100 mg/l ml of water. Particularly preferred sulfonate saltsinclude methanesulfonate, ethanesulfonate, benzenesulfonate andp-toluenesulfonate salt forms.

[0021] An “excipient” as used herein means any pharmaceuticallyacceptable inactive component of the composition. As is well known inthe art, excipients include diluents, binders, lubricants,disintegrants, colorants, preservatives, pH-adjusters etc. Theexcipients are selected based on the desired physical aspects of thefinal form: e.g., obtaining a tablet with desired hardness andfriability, being rapidly dispersible and easily swallowed, etc. Thedesired release rate of the active substance from the composition afterits ingestion also plays a role in the choice of excipients.

[0022] Suitable excipients for use in this invention include:

[0023] a diluent such as calcium hydrogen phosphate, lactose, mannitoletc.

[0024] a binder such as microcrystalline cellulose or a modifiedcellulose, povidone etc.

[0025] a disintegrant such as sodium starch glycollate, crosspovidone

[0026] a lubricant such as magnesium stearate, sodium stearyl fumarate

[0027] a colorant, taste masking agent etc.

[0028] It is particularly advantageous that the composition of theinvention is not specifically required to use anhydrous excipients orhydrophobic excipients, although such excipients may be used. Similarly,the present invention does not have to strictly control the watercontent in the excipients prior to their use or incorporation. In apreferred embodiment, no decolorization agent is required to be presentin the composition of the invention, although such may be present ifdesired. “Decolorization agent” as used herein means an agent which isbeing added to a composition with the aim to protect the activesubstance against reactions that form colored products, such as anantioxidant (e.g. ascorbic acid etc.), free radical scavenger (e.g.tocopherol etc.) etc.

[0029] It has now been discovered that the undesired impurity A ispreferentially formed in an aqueous alkaline environment from theparoxetine free base. Accordingly, it can be advantageous to employmultiple strategies to reduce or prevent coloration. These strategiesinclude limiting the amount of added water remaining in the composition,controlling the pH of the composition to be sufficiently acidic,limiting the presence of oxygen during formation and/or storage, andreducing the level of paroxetine free base impurity in the active.Indeed, using one or more of these strategies can control the coloringproblem encountered with other paroxetine salt forms includingparoxetine hydrochloride salt forms, whether made from a dry or wetprocess. For example controlling the pH to 6.5 or less, controlling(reducing) the level of free base impurity, and/or quickly removing 98%or more of the water used in granulating should allow for the formationof a color stable paroxetine hydrochloride pharmaceutical composition.Additionally, for reasons that are not entirely clear, paroxetinesulfonate salts can provide superior color stability in comparison toparoxetine hydrochloride salts.

[0030] The compositions of the present invention, including granulatesand final dosage forms, preferably have a pH of 6.5 or less, morepreferably a pH of 6.0 or less, including about 5.5 or less. Typically,the pH of the dosage form or a granulate is within the range of 4.5 to6.5, more typically from 5.0 to 6.0. The pH is determined by forming aslurry of the solid composition with water and measuring the pH of theslurry, as is understood by workers skilled in the art regarding the pHof a solid composition. The concentration of the composition in theslurry is 20 wt %. The pH is measured by any standard technique. The pHcan be adjusted by the proper selection of excipients.

[0031] In this respect, a proper grade of calcium phosphate (anhydrousor hydrated) having a pH around 5.5 is preferred to be used as asuitable filler. Commercially available/pharmaceutically acceptablecalcium phosphates are generally alkaline; i.e. pH greater than 7 whenmeasured as described above in a 20% slurry. For instance, DI-TAB, acommercially available dibasic calcium phosphate dihydrate, is reportedas having a pH of about 7.4. Nonetheless some forms and grades ofcalcium phosphate are acidic or neutral pH. This lower pH can be due tothe species of calcium phosphate as well as the treatment duringprocessing of the material, such as in removing impurities/washing. Forexample, dibasic calcium phosphate anhydrate is generally considered tohave a pH of about 7.3 whereas A-Tab™ (Rhodia), also a dibasic calciumphosphate anhydrate, has a pH of about 5.1. Further examples ofcommercially available non-alkaline calcium phosphates include DiCAFOS P(Budenheim) having a pH of about 7 and Fujicalin SG (Fuji) having a pHfrom 6.1-7.2. By using a non-alkaline calcium phosphate as an excipient,a pharmaceutical composition meeting the desired pH can be attained.Alternatively, a blend of calcium phosphates, even one using acidic andalkaline calcium phosphates, can be used to achieve the desired acidicpH of the composition. The pH can also be assisted by selection of anyother excipients in the composition. For instance, another example of auseful acidic excipient is the disintegrant Explotab(TM) of Penwest,which is a cross-linked, low substituted sodium starch glycollate.

[0032] Especially advantageous compositions of the invention compriseparoxetine sulfonate salt in the absence of a hydrosoluble orhydrophilic diluent such as lactose or microcrystalline cellulose.Unlike the suggestions in CH 690 024, wherein such ahydrosoluble/hydrophillic diluent is taught for use with paroxetinemesylate, it has been discovered that surprisingly the use of only acalcium phosphate diluent, such as calcium hydrogen phosphate anhydrate,exhibits an additional advantageous feature for industrial application;namely that it efficiently masks or prevents the bitter taste ofparoxetine. Thus, after the paroxetine salt, especially paroxetinemesylate, and diluent composition is mixed with a disintergant and alubricant and compressed into tablets, the tablets may be administeredto a human patient without need of a taste-masking coating or a similartool for taste masking. To the contrary, the presence of a hydrosolubleor hydrophilic diluent rather pronounces the bitter taste of paroxetineso that such tablet is unpleasant to be swallowed unless film-coated.Pharmaceutical compositions comprising paroxetine methane sulfonate andcalcium hydrogen phosphate, optionally containing conventionallubricants and/or disintegrants, form a particular aspect of ourinvention. Of course, these particular compositions can be made by a dryprocess (dry mixing followed by direct compression) as well as by any ofthe wet processes known or described herein, and still provide theunexpected taste masking result.

[0033] In general, the compositions of the present invention preferablyhave a remaining added water content of 2.0 wt % or less, preferably 1.3wt % or less, more preferably 1.2 wt % or less, still more preferably1.0 wt % or less, and most preferably 0.8 wt % or less. The “remainingadded water” content refers to the remaining water that was added in theaid of mixing and does not include water that was present in theexcipients such as bound water in microcrystalline cellulose. If thecomposition was made by a dry process, then the remaining added watercontent is 0.0%. Generally, each formulation has a threshold amount ofremaining added water content below which the dimeric impurity A isformed either very little or not at all. Above this threshold amount,the impurity A is formed abundantly. The occurrence of the impurity isthus not usually a linear function of water content. By controlling theadded water content in the final granulate, a color stable product canbe attained, even if made by a conventional wet granulation process. Thesame is true for the final product solid dosage form.

[0034] Granules made according to the present invention can be useddirectly but usually are processed into any of a variety of dosage formsas mentioned above. Typically, the granules, optionally with additionalexcipients, are compressed into tablets. The paroxetine tablets may becoated by a suitable film-coating, e.g., similar to the coating used inthe commercially available tablets of paroxetine hydrochloridehemihydrate. Suitable techniques of coating include aqueous coating,non-aqueous coating or a melt coating process. Coating mixtures arecommercially available. Coating for extended or delayed release of theactive substance is also applicable to the composition of our invention.Coating mixtures may contain suitable colorants.

[0035] The paroxetine-containing granulate may also be used forpreparation of capsulized unit dosage forms. The dry granulate may beoptionally screened and/or pelletized by methods known per se to obtainparticulate material of uniform size and shape. The granules or pelletsare then filed into suitable capsules made from e.g. gelatine,hydroxypropylmethyl cellulose or starch. Capsules having low moisturecontent are preferred. Coating of the produced granulate is normally notnecessary.

[0036] Paroxetine-containing granulate may also be filled into sachetscontaining the required unit dose of paroxetine. Such sachets areadministered by dispersing or dissolving the content thereof in asuitable liquid, e.g. in water, and drinking. The compositions maycontain suitable taste-masking excipients, flavors or sweeteners.

[0037] Another suitable final form comprising granulates according tothe present invention are effervescent tablets, granulates or powders.They are formed by mixing the granulate with a suitable effervescentsystem by methods known per se.

[0038] The compositions of the present invention can be made by anyconventional process including dry process such as dry blending, drygranulation, and direct compression as well as by wet processes such aswet granulation. In some embodiments, especially for paroxetinesulfonate salts, it is preferable to use water in the aide of mixing.For example, a granulate is formed by combining a paroxetine sulfonatesalt and at least one excipient and mixing them in the presence of addedwater, followed by drying to remove substantially all of the addedwater. The resulting population of granules, or the “granulate,” isdried to have a an average content of remaining “added water” of 2.0 wt% or less, preferably 1.3 wt % or less, more preferably 1.0 wt % or lessand even 0.8 wt % or less, based on the total weight of the granulate.

[0039] Typically the water is added in one of two ways, although theinvention is not limited thereto. In a first method, water is added toparoxetine sulfonate and an excipient. The amount of water added isnormally between 5 and 25 wt %, more typically between 10 and 20 wt %,based on the total weight of the resulting wet mixture. More water canbe added, i.e., 30 wt %, 40 wt % or even 50 wt %, but some difficultiesmay be encountered concerning possible modifications of the excipient(for instance microcrystalline cellulose may change crystal form) andadditional energy will be needed to remove the higher amounts of addedwater. The paroxetine sulfonate salt and the excipient are normally inpowder form and pre-mixed or blended to form a powder bed prior to theaddition of water. Alternatively, the excipient can be in granulate formand admixed with the paroxetine sulfonate powder. The excipient isgenerally one or more diluents such as calcium phosphate,microcrystalline cellulose, or both.

[0040] The wet mixture is stirred, usually under vigorous conditions, toform a homogeneous mixture. The added water is removed from the wettedmixture normally as rapidly as possible. The added water can be removedby heating as well as by passing a nitrogen gas stream over (or through)the mixture, or a combination thereof. The use of a nitrogen gas streamis also advantageous in that the presence of oxygen is reduced oravoided. The drying of the added water can occur after, during orsimultaneously with the mixing/stirring step. To reduce the chance ofcolor formation, the average residence time of the added water incontact with the paroxetine sulfonate and excipient(s) during the mixingand drying steps is generally less than 3 hours, more typically lessthan 2 hours, more typically less than 1.5 hours, frequently less thanor equal to 1 hour and is normally in the range of 30 to 90 minutes,more preferably 30 to 60 minutes, depending upon the apparatus volumes,etc. Upon completion of the stirring and drying steps, a paroxetinesulfonate-containing granulate is obtained having a low added watercontent as described above.

[0041] For preparation of a final mixture for compressing into a tabletcore (pre-compression mixture), the above paroxetinesulfonate-containing granulate is optionally mixed with additionaldiluent(s), a disintegrant and/or a lubricant such as magnesiumstearate, in a suitable mixer, e.g. in a free-fall mixer. Thepre-compression mixture is finally compressed into tablets by a suitabletableting press under ordinary conditions. The other excipients formixing with the granulate should also be chosen, in terms of kind andgrade, such that the final pre-compressing mixture exhibits a pH valueof 6.5 or less as described above.

[0042] A second method for forming the granulate involves combining theadded water with the paroxetine sulfonate to form an aqueous solution ofparoxetine sulfonate. This aqueous solution is then added to at leastone excipient. As in the first method, the excipient can be in powder orgranulate form. The aqueous solution is generally a concentratedsolution having at least 10 wt % paroxetine sulfonate, preferably atleast 30 wt %, and more preferably at least 40 wt % paroxetinesulfonate. By using a concentrated solution, less water is needed,thereby saving energy in the drying step and allowing for faster dryingtimes. These highly concentrated solutions are possible because of theadvantageous water solubility of paroxetine sulfonate in comparison toother paroxetine salts such as paroxetine hydrochloride. The stirringand drying steps as well as the work up of the granulate into apre-compression composition are carried out as described above.

[0043] A preferred formulation made by this process comprises adding theconcentrated paroxetine sulfonate aqueous solution to either calciumhydrogen phosphate or microcrystalline cellulose followed by stirringand drying to form a paroxetine-containing granulate. To the formedgranulate is then mixed the other one of the calcium hydrogen phosphateor microcrystalline cellulose which was not used to form the granulatealong with sodium starch glycolate (a disintegrant) and magnesiumstearate. The resulting mixed composition is ready for compression intotablets. An example of this composition contains 7.24 wt % paroxetinesulfonate (as the equivalent free base), 57.76 wt % of CaHPO₄, 30.0 wt %microcrystalline cellulose (Avicel PH 101), 4.0 wt % sodium starchglycolate, and 1 wt % magnesium stearate.

[0044] In the aqueous granulation procedure for preparation of tabletsor capsules of paroxetine mesylate, microcrystalline cellulose andvarious forms and grades of calcium phosphate, typically calciumhydrogen phosphate, are the preferred solid diluents. However, thecomposition of this invention and the process for its preparation is notlimited thereto. Alternate diluents include mono- and di saccharidesugars such as lactose, mannitol, lactitol, xylitol or combinationsthereof.

[0045] Alternatively, a dry process can also be carried out wherein theparoxetine salt is dry blended with an excipient, typically a calciumphosphate or microcrystalline cellulose, or both and optionally with adisintegrant. After blending, the mixture is compressed into a tablet.

[0046] For both wet and dry processes, it is sometimes advantageous toprovide multiple mixing steps to facilitate high quality, homogenousmixing. For example, a portion of the binder(s) and/or disintegrant(s)are mixed with the paroxetine salt, optionally with the aide of water asdescribed above. To this mixture the remainder of the binder(s) and/ordisintegrant(s) are mixed. To this resulting mixture the remainingexcipients such as a lubricant(s) are mixed. Such partial mixing can usemore steps or fewer steps and can split intermediate mixtures intoportions to facilitate apparatus volumes. Additionally, excipients canbe pre-treated by techniques known in the art as desired, including wetgranulation and dry granulation treatments. The binders or fillers suchas calcium phosphate anhydrate can be pretreated with water and dried(<0.5% water) before being combined with the paroxetine salt orsolution.

[0047] The composition of the present invention can be used to treat orprevent the following disorders: depression, obsessive compulsivedisorder, alcoholism, anxiety, panic disorder, chronic pain, obesity,senile dementia, migraine, bulimia, anorexia, social phobia,pre-menstrual syndrome, adolescent depression, trichotillomania,dysthymia, substance abuse etc. Most suitably, the composition of theinvention is applied for treatment of depression, obsessive compulsivedisorder and panic disorder.

[0048] The treatment or prevention of any one or more of the abovedisorders is performed by administering orally the compositioncomprising an effective and/or prophylactic amount of the paroxetinesulfonate to a patient in need thereof. The patient can be a mammalincluding a human, a dog, a horse, or a monkey.

[0049] The composition of this invention is advantageously presented asa unit dose composition, preferably in a form of a tablet or a capsule,comprising paroxetine sulfonate equivalent to from 1 to 200 mg ofparoxetine free base, more usually from 5 to 100 mg, for example from 10to 50 mg. Typical tablet doses are 10, 20, 30, and 40 mg. Such acomposition is normally taken by a human patient from 1 to 6 timesdaily, but more usually once or twice daily, with the total amount ofparoxetine sulfonate administered being generally between 5 to 400 mg ofparoxetine. A suitable daily dose is from 0.05 to 6 mg/kg, orepreferably 0.14 to 0.86 mg/kg.

EXAMPLES Example 1

[0050] Granulate of Paroxetine Mesylate for Tablet Production

[0051] 1. Prepare a pre-blend of 3177.5 g of calcium hydrogen phosphateanhydrate (A-TAB pH 5.1) and 29.75 g of sodium starch glycollate bymixing for 5 minutes in a high-shear granulator.

[0052] 2. Prepare a solution of 258.3 g of paroxetine mesylate in 350 mlof water.

[0053] 3. Add the solution to the pre-blend granulate from the step 1 atambient temperature.

[0054] 4. Dry the wet granulate at 40° C. under diminished pressure andnitrogen flow to less than 1% water content.

[0055] 5. Mix the resulted granulate with 29.75 g of sodium starchglycollate for 15 minutes in a free-fall mixer; add 70.0 g of magnesiumstearate to the mixture and mix for 5 minutes.

[0056] Tablet cores containing 40 mg of paroxetine are prepared from theresulting granulate (pH=5.53) on a suitable tableting machine (tabletweight 713 mg, punch diameter 10 mm, hardness 80 N). Despite the use ofwater to aid in the mixing, these tablets did not turn pink upon storageunder accelerated conditions (40° C./75%RH) packaged inPVC/PE/PVDC—aluminium blisters or in HDPE containers.

Example 2

[0057] Granulate of Paroxetine Mesylate for Tablets

[0058] The process as in Example 1 was maintained with the modificationthat the steps 3 and 4 are performed simultaneously, at 40° C. The timenecessary for adding the paroxetine mesylate aqueous solution is approx.15 minutes; for drying approx. 45 minutes. The composition has a pH of5.37.

Example 3

[0059] Tablets of paroxetine mesylate are made having the followingcomposition: Paroxetine mesylate 12.915 mg 25.83 mg 38.745 mg 51.66 mg(10 mg equiv.) (20 mg equiv.) (30 mg equiv.) (40 mg equiv.) Calciumhydrogen 158.88 mg 317.75 mg 476.64 mg 635.50 mg phosphate anhydrate pH5.1 Sodium starch 2.975 mg 5.95 mg 8.925 mg 11.90 mg glycollateMagnesium stearate 3.50 mg 7.00 mg 10.50 mg 14.00 mg

[0060] The tablets are made as follows. Paroxetine mesylate is mixedwith calcium hydrogen phosphate. 10% water is added and the mixturegranulated and dried to an added water content of around 1%. Theresulting granulate is mixed with the sodium starch glycollate, andmagnesium stearate in a free fall mixer and compressed into tablets;each tablet having the above composition. The pH varies from 5.2 to 5.8depending upon the batches of excipients used.

Example 4

[0061] Tablets of Paroxetine mesylate Paroxetine mesylate 51.66 mg(equivalent to 40 mg of paroxetine free base) Calcium hydrogen phosphate411.83 mg Microcrystalline cellulose 213.92 mg Sodium starch glycollate28.52 mg Magnesium stearate 7.13 mg

[0062] Tablets having the above composition are made as follows.Paroxetine mesylate is mixed with calcium hydrogen phosphate. 10% wateris added and the mixture granulated and dried to an added water contentof around 1%. The resulting granulate is mixed with microcrystallinecellulose, sodium starch glycollate, and magnesium stearate in a freefall mixer and compressed into tablets; each tablet having the abovecomposition. The pH is 5.45.

Example 5

[0063] The same tablets as Example 4 are made, but first a paroxetinemesylate aqueous solution having a paroxetine mesylate concentration ofabout 30 wt % is formed. This solution is added to microcrystallinecellulose and dried to form a granulate. The produced granulate is mixedwith calcium hydrogen phosphate, sodium starch glycollate, and magnesiumstearate in a free fall mixer and compressed into tablets. The pH is5.26.

Example 6

[0064] Tablets of Paroxetine mesylate Composition per 1 g of tabletcore: Paroxetine mesylate 72 mg Mannitol 300 mg Calcium hydrogenphosphate 533 mg Croscarmellose sodium 20 mg Povidone 30 mg Magnesiumstearate 15 mg

[0065] 1. Granulate 30% solution of paroxetine mesylate with a pre-blendmixture of mannitol, calcium hydrogen phosphate and croscarmellosesodium and dry to water content less than 1%.

[0066] 2. Mix the dried and screened granulate with povidone andmagnesium stearate. The granulate is suitable for compression intotablets containing 20 mg paroxetine.

Example 7

[0067] Tablets of Paroxetine mesylate Composition of 1 g of tablet core:Paroxetine mesylate 72 mg Microcrystalline cellulose 290 mg Calciumhydrogen phosphate 580 mg Sodium starch glycollate 28 mg Hydroxypropylcellulose 20 mg Magnesium stearate 10 mg

[0068] 1. Granulate 30% aqueous solution of paroxetine mesylate with apre-blend mixture of microcrystalline cellulose, calcium hydrogenphosphate and sodium starch glycollate and dry.

[0069] 2. Mix the dried and screened granulate with hydroxypropylcellulose and magnesium stearate.

[0070] The granulate is suitable for compression into tablets containing20 mg paroxetine and having a pH of 5.14.

[0071] In the following Examples 8-19, the compositions listed areprocessed substantially as in Example 1, e.g. a granulate is prepared byusing a concentrated aqueous solution of paroxetine mesylate and the dryparoxetine mesylate-containing granulate with water content less than 1%is mixed with the remaining excipients to prepare a bulk material forprocessing into the listed final forms by conventional methods.

Example 8

[0072] Composition of effervescent tablets (per 1 g) a) granulateParoxetine mesylate 26 mg Mannitol 166 mg b) Effervescent system Sodiumbicarbonate 378 mg Citric acid anhydrous 400 mg Saccharin sodium 9 mgAspartame 3 mg Sodium chloride 1.5 mg Sodium lauryl sulfate 0.05%Flavour 16 mg

Example 9

[0073] Composition of effervescent tablets (per 1 g) a) granulateParoxetine mesylate 26 mg Isomaltose 203 mg b) Effervescent systemSodium bicarbonate 336 mg Citric acid 400 mg Sodium chloride 1.5 mgNeo-DHC 5 mg Sodium lauryl sulfate 0.5 mg Flavour 18 mg

Example 10

[0074] Composition of dispersible tablets (per 1 g) a) granulateParoxetine mesylate 72 mg Pregelatinized starch 380 mg Microcrystallinecellulose 380 mg Sodium starch glycollate 100 mg b) Other excipientsHydroxypropyl cellulose 20 mg Sodium saccharin 8 mg Sodium stearylfumarate 10 mg Colloidal silicine dioxide 10 mg Flavour 20 mg

Example 11

[0075] Composition of dispersible tablets (per 1 g) a) granulateParoxetine mesylate 72 mg Mannitol 500 mg Microcrystalline cellulose 260mg Crosspovidone 100 mg b) Other excipients Sodium saccharin 8 mg Sodiumstearyl fumarate 10 mg Colloidal silicon dioxide 10 mg Flavour 20 mg

Example 12

[0076] Composition of sublingual tablets (per 1 g) a) granulateParoxetine mesylate 72 mg Sucrose 650 mg Sorbitol 258 mg b) Otherexcipients Sodium stearyl fumarate 20 mg

Example 13

[0077] Composition of sublingual tablets (per 1 g) a) granulateParoxetine mesylate 72 mg Mannitol 318 mg Microcrystalline cellulose 600mg b) Other excipients Magnesium stearate 10 mg

Example 14

[0078] Composition of controlled release tablets with hydrophilic matrix(per 1 g) a) granulate Paroxetine mesylate  72 mg Hydroxypropylmethylcellulose 700 mg Hydroxypropyl cellulose 168 mg b) other ingredientsPovidone  40 mg Sodium stearyl fumarate  20 mg

Example 15

[0079] Composition of controlled release tablets with hydrophobic matrix(per 1 g) a) granulate Paroxetine mesylate  72 mg Microcrystallinecellulose 520 mg b) other ingredients Glyceryl behenate 200 mg Glycerylpalmitostearate 200 mg Sodium stearyl fumarate  8 mg

Example 16

[0080] Composition for immediate-release hard-shell capsules (per 1 g)a) granulate Paroxetine mesylate  72 mg Maltodextrin 820 mgPregelatinized starch  80 mg b) other ingredients crosspovidone  20 mgcolloidal silicone dioxide  8 mg

[0081] The produced granulate should be sieved and filled per 333 mginto Size 2 capsule.

Example 17

[0082] Composition for enteric-release hard-shell capsules (per 1 g) a)granulate Paroxetine mesylate 72 mg Sucrose-starch non-pareill seeds 790mg Eudragit L 30 D 55 123.5 mg b) other ingredients talc 7 mgpolyethylene glycol 6000 7 mg silicone dioxide 0.5 mg

[0083] The produced granulate should be sieved and filled per 333 mginto Size 2 capsule.

Example 18

[0084] Composition for controlled release hard-shell capsules (per 1 g)a) granulate Paroxetine mesylate  72 mg microcrystalline cellulose 850mg Ethylcellulose  60 mg Hydroxypropylcellulose  18 mg b) otheringredients none

[0085] The produced granulate should be sieved and filled per 350 mginto Size 2 capsule.

Example 19

[0086] Composition for oral sachets (per 1 g) a) granulate Paroxetinemesylate  5 mg Sucrose 565 mg Mannitol 377 mg Povidone  28 mg b) otheringredients saccharin sodium  10 mg Flavour  15 mg

[0087] The invention having been described, it will be readily apparentto those skilled in the art that further changes and modifications inactual implementation of the concepts and embodiments described hereincan easily be made or may be learned by practice of the invention,without departing from the spirit and scope of the invention as definedby the following claims.

We claim:
 1. A solid paroxetine composition comprising a paroxetine salt and an excipient wherein said composition has a pH of 6.5 or less.
 2. The composition according to claim 1, wherein said pH is within the range of about 4.5 to 6.5.
 3. The composition according to claim 1, wherein said paroxetine salt is a paroxetine sulfonate salt or a paroxetine hydrochloride salt.
 4. The composition according to claim 3, wherein said pH is less than 6.0.
 5. The composition according to claim 3, wherein said pH is within the range of about 4.5 to 6.5.
 6. The composition according to claim 5, wherein said paroxetine salt is paroxetine methane sulfonate or paroxetine hydrochloride.
 7. The composition according to claim 6, wherein said paroxetine salt is paroxetine methane sulfonate.
 8. The composition according to claim 1, wherein the excipient is acidic calcium phosphate.
 9. The composition according to claim 1, wherein said composition is a tablet and said paroxetine salt is contained in a pharmaceutically effective amount and is selected from paroxetine sulfonate salts and paroxetine hydrochloride salts.
 10. The composition according to claim 9, wherein said excipient is selected from the group consisting of a diluent, a binder, a disintegrant, a lubricant, a colorant, or a combination of two or more thereof.
 11. The composition according to claim 10, which does not contain a hydrosoluble or hydrophilic diluent.
 12. The composition according to claim 11, which does not contain a taste masking coating.
 13. The composition according to claim 11, which comprises calcium phosphate, a lubricant and a disintegrant.
 14. The composition according to claim 13, wherein said paroxetine salt is paroxetine methane sulfonate salt.
 15. A paroxetine solid dosage form comprising a paroxetine sulfonate salt and having been made with the aid of water.
 16. The dosage form according to claim 15, wherein said dosage form is a tablet or a capsule.
 17. The dosage form according to claim 16, wherein said paroxetine sulfonate salt is paroxetine methane sulfonate.
 18. The dosage form according to claim 15, wherein said paroxetine sulfonate salt was combined as an aqueous solution with at least one excipient in preparing said dosage form.
 19. The dosage form according to claim 18, wherein said dosage form has a pH of 6.5 or less.
 20. A granulate formed by mixing water, paroxetine sulfonate, and at least one excipient and drying the resulting mixture.
 21. The granulate according to claim 20, wherein said mixing was accomplished by adding together an aqueous solution of said paroxetine sulfonate salt with said at least one excipient.
 22. The granulate according to claim 21, wherein said aqueous solution of paroxetine sulfonate salt is a concentrated solution having at least about a 10 wt % concentration of paroxetine sulfonate.
 23. The granulate according to claim 22, wherein said aqueous solution has a paroxetine sulfonate salt concentration of at least about 30 wt %.
 24. The granulate according to claim 20, wherein said mixing and said drying are carried out simultaneously.
 25. The granulate according to claim 21, wherein said aqueous solution of paroxetine sulfonate was added to a powdered or granulated blend of said at least one excipient.
 26. The granulate according to claim 20, wherein said granulate has an average remaining added water content of about 2.0 wt % or less.
 27. The granulate according to claim 26, wherein said granulate has an average remaining added water content of about 1.0 wt % or less.
 28. The granulate according to claim 27, wherein said granulate has an average remaining added water content of about 0.8 wt % or less.
 29. The granulate according to claim 20, wherein said granulate composition exhibits a pH value of 6.5 or less.
 30. The granulate according to claim 29, wherein said granulate has a pH of about 6.0 or less.
 31. The granulate according to claim 29, wherein said granulate has a pH within the range of 4.5 to 6.5.
 32. The granulate according to claim 20, wherein said paroxetine sulfonate salt is paroxetine methane sulfonate.
 33. A process, which comprises: mixing an aqueous solution containing at least 10 wt % of a paroxetine sulfonate with at least one solid excipient; and drying to form a granulate.
 34. The process according to claim 33, wherein said drying step produces a granulate having a remaining added water content of about 2.0 wt % or less.
 35. The process according to claim 34, wherein said drying step produces a granulate having a remaining added water content of about 1.3 wt % or less.
 36. The process according to claim 35, wherein said drying step produces a granulate having a remaining added water content of about 1.0 wt % or less.
 37. The process according to claim 36, wherein said drying step produces a granulate having a remaining added water content of about 0.8 wt % or less.
 38. The process according to claim 33, wherein said aqueous solution concentration of said paroxetine sulfonate is at least 30 wt %.
 39. The process according to claim 38, wherein said aqueous solution concentration of said paroxetine sulfonate is at least 40 wt %.
 40. The process according to claim 33, wherein said mixing and drying steps are performed concurrently.
 41. The process according to claim 33, wherein said solid excipient is a granulate.
 42. The process according to claim 33, which further comprises optionally mixing additional excipients with said granulate and pressing said granulate composition into a tablet.
 43. The process according to claim 42, which further comprises film coating said tablet.
 44. The process according to claim 33, which further comprises filling said granulate into a capsule or sachet.
 45. The process according to claim 33, which further comprises processing said granulate into effervescent tablets, sublingual tablets, controlled release tablets or delayed release tablets.
 46. The process according to claim 33 wherein the excipients comprise at least one ingredient selected from the group consisting of binders, disintegrants, and fillers.
 47. The process according to claim 46, wherein said granulate exhibits a pH value of 6.5 or less.
 48. The process according to claim 47, wherein said granulate has a pH of about 6.0 or less.
 49. The process according to claim 47, wherein said granulate has a pH of about 5.5 or less.
 50. The process according to claim 33, wherein said paroxetine sulfonate is paroxetine methane sulfonate. 